Neutralization activity in a geographically diverse East London cohort of human immunodeficiency virus type 1-infected patients: clade C infection results in a stronger and broader humoral immune response than clade B infection.
| dc.contributor.author | Dreja, Hanna | |
| dc.contributor.author | O'Sullivan, Eithne | |
| dc.contributor.author | Pade, Corinna | |
| dc.contributor.author | Greene, Kelli M | |
| dc.contributor.author | Gao, Hongmei | |
| dc.contributor.author | Aubin, Keith | |
| dc.contributor.author | Hand, James | |
| dc.contributor.author | Isaksen, Are | |
| dc.contributor.author | D'Souza, Carl | |
| dc.contributor.author | Leber, Werner | |
| dc.contributor.author | Montefiori, David | |
| dc.contributor.author | Seaman, Michael S | |
| dc.contributor.author | Anderson, Jane | |
| dc.contributor.author | Orkin, Chloe | |
| dc.contributor.author | McKnight, Aine | |
| dc.coverage.spatial | England | |
| dc.date.accessioned | 2011-06-21T17:27:29Z | |
| dc.date.issued | 2010-11 | |
| dc.description.abstract | The array of human immunodeficiency virus (HIV) subtypes encountered in East London, an area long associated with migration, is unusually heterogeneous, reflecting the diverse geographical origins of the population. In this study it was shown that viral subtypes or clades infecting a sample of HIV type 1 (HIV-1)-positive individuals in East London reflect the global pandemic. The authors studied the humoral response in 210 treatment-naïve chronically HIV-1-infected (>1 year) adult subjects against a panel of 12 viruses from six different clades. Plasmas from individuals infected with clade C, but also plasmas from clade A, and to a lesser degree clade CRF02_AG and CRF01_AE, were significantly more potent at neutralizing the tested viruses compared with plasmas from individuals infected with clade B. The difference in humoral robustness between clade C- and B-infected patients was confirmed in titration studies with an extended panel of clade B and C viruses. These results support the approach to develop an HIV-1 vaccine that includes clade C or A envelope protein (Env) immunogens for the induction of a potent neutralizing humoral response. | |
| dc.description.version | Version of Record | |
| dc.identifier | ||
| dc.identifier | vir.0.024224-0 | |
| dc.identifier.eissn | 1465-2099 | |
| dc.identifier.uri | ||
| dc.language | eng | |
| dc.language.iso | en_US | |
| dc.publisher | Microbiology Society | |
| dc.relation.ispartof | J Gen Virol | |
| dc.relation.isversionof | 10.1099/vir.0.024224-0 | |
| dc.relation.journal | Journal of General Virology | |
| dc.subject | Antibodies, Neutralizing | |
| dc.subject | Cohort Studies | |
| dc.subject | Female | |
| dc.subject | Genotype | |
| dc.subject | HIV Antibodies | |
| dc.subject | HIV Protease | |
| dc.subject | HIV Reverse Transcriptase | |
| dc.subject | HIV-1 | |
| dc.subject | Humans | |
| dc.subject | London | |
| dc.subject | Male | |
| dc.subject | Neutralization Tests | |
| dc.subject | Sequence Analysis, DNA | |
| dc.title | Neutralization activity in a geographically diverse East London cohort of human immunodeficiency virus type 1-infected patients: clade C infection results in a stronger and broader humoral immune response than clade B infection. | |
| dc.title.alternative | ||
| dc.type | Journal article | |
| duke.contributor.orcid | Montefiori, David|0000-0003-0856-6319 | |
| duke.date.pubdate | 2010-11-0 | |
| duke.description.issue | ||
| duke.description.volume | 91 | |
| pubs.author-url | ||
| pubs.begin-page | 2794 | |
| pubs.end-page | 2803 | |
| pubs.issue | Pt 11 | |
| pubs.organisational-group | Clinical Science Departments | |
| pubs.organisational-group | Duke | |
| pubs.organisational-group | Duke Human Vaccine Institute | |
| pubs.organisational-group | Institutes and Centers | |
| pubs.organisational-group | School of Medicine | |
| pubs.organisational-group | Surgery | |
| pubs.organisational-group | Surgery, Surgical Sciences Section for AIDS Research & Development | |
| pubs.publication-status | Published | |
| pubs.volume | 91 |